JPMorgan lowered the firm’s price target on Oric Pharmaceuticals to $18 from $19 and keeps an Overweight rating on the shares. The analyst updated the company’s model to include expenses and share count.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Oric Pharmaceuticals price target raised to $21 from $15 at H.C. Wainwright
- Oric Pharmaceuticals price target raised to $17 from $14 at Oppenheimer
- Oric Pharmaceuticals price target lowered to $25 from $27 at Baird
- Oric Pharmaceuticals files automatic mixed securities shelf
- ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
